Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cardiac Electrophysiology Without Fluoroscopy / / edited by Riccardo Proietti, Yan Wang, Yan Yao, Guo Qiang Zhong, Shu Lin Wu, Félix Ayala-Paredes
| Cardiac Electrophysiology Without Fluoroscopy / / edited by Riccardo Proietti, Yan Wang, Yan Yao, Guo Qiang Zhong, Shu Lin Wu, Félix Ayala-Paredes |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (241 pages) |
| Disciplina | 612.813 |
| Soggetto topico |
Cardiology
Cardiac imaging Cardiac Imaging |
| ISBN | 3-030-16992-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Clinical Studies of a purely 3D Navigation in Interventional Managements of Tachyarrhythmia -- Radiation exposure and safety for the electrophysiologist -- Ablation Energy Sources-Principles and Utility in Ablation without Fluoroscopy -- 3D mapping and reduction in radiation exposure -- Catheter Placement and Model reconstruction -- Learning curve for zero-fluoroscopic procedure -- Atrioventricular Nodal Reentrant Tachycardia (AVNRT) with zero-fluoroscopic procedure -- AV Nodal re-entrant tachycardia ablation without fluoroscopy -- Non-Fluoroscopic Catheter Ablation of Accessory Pathways -- Focal atrial tachycardia -- Ablation of atrial flutter with zero fluoroscopy approach -- Non-Fluoroscopic Catheter Ablation of Atrial Fibrillation -- Non-Fluoroscopic Catheter Ablation of Idiopathic Ventricular Arrhythmias -- Ventricular Tachycardia with Structural Heart Disease -- Reduction on radiation exposure in pediatric population undergoing ablation procedures -- Complications of RFCA and Prevention Method -- Safety of zero-fluroscopic procedure during pregnancy -- Cost optimization when using 3-D mapping systems for a non fluoro EP lab -- Zero-fluoroscopic implantation of cardiac electronic Device -- Cardiac Resynchronization Therapy (CRT) guided by 3D mapping system -- Transesophageal Electrophysiological Study without fluoroscopy. |
| Record Nr. | UNINA-9910349362403321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Direct oral anticoagulants : from pharmacology to clinical practice / / Riccardo Proietti [and four others], editors
| Direct oral anticoagulants : from pharmacology to clinical practice / / Riccardo Proietti [and four others], editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (283 pages) |
| Disciplina | 615.718 |
| Soggetto topico |
Anticoagulants (Medicine)
Anticoagulants (Medicina) |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-74462-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- 1: The Coagulative Cascade -- Introduction -- The Cell-Based Model of Blood Coagulation -- The Effect of Oral Anticoagulants on the Coagulation Cascade -- Conclusions -- References -- 2: Clinical Indications for Direct Acting Oral Anticoagulants -- Introduction -- Nonvalvular Atrial Fibrillation -- Venous Thromboembolism -- Coronary Artery Disease -- Left Ventricular Thrombus -- Rheumatic Heart Disease -- Heparin-Induced Thrombocytopenia -- Myocardial Injury After Noncardiac Surgery -- Heart Failure in Sinus Rhythm -- Embolic Stroke of Undetermined Source -- Mechanical Valves -- Left Ventricular Assist Device -- References -- 3: Pharmacokinetics and Pharmacodynamics of DOAC -- Introduction -- Physico-Chemical Properties -- Pharmacodymanics of DOACs -- Mechanism of Action -- Pharmacokinetics of DOACs -- Absorption -- Distribution -- Metabolism -- Excretion -- Conclusions -- References -- 4: Drug-Drug Interaction with DOACs -- Introduction -- General Considerations -- DDI with Antiarrhythmic Drugs -- DDI with Antiplatelet and Antithrombotic Drugs -- DDI with NSAIDs Drugs -- DDI with Statins and Lipid-Modifying Agents -- DDI with Antibiotics and Antifungal Drugs -- DDI with Antacid Drugs -- DDI with Antineoplastic and Immune-Modulating Agents -- DDI with Antiepileptic Drugs -- DDIs with Anti-Human Immunodeficiency (HIV) and Anti-Hepatitis C Virus (HCV) Drugs -- DDIs with Monoclonal Antibodies and Interleukin 6 (IL6) -- Conclusions -- References -- 5: Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery -- Introduction -- Indications for Reversal -- Emergency Surgery and Urgent Procedures -- Life-Threatening and Uncontrolled Bleeding -- General Approach -- Assessment of Anticoagulation Status -- Specific and Nonspecific Agents -- Dabigatran Reversal: Idarucizumab (Praxbind®) -- Clinical Pharmacology.
Dosage and Administration -- Efficacy and Safety -- Use in Clinical Practice -- Factor Xa Inhibitor (Rivaroxaban and Apixaban) Reversal: Andexanet Alfa (Andexxa® -- Ondexxya®) -- Clinical Pharmacology -- Dosage and Administration -- Efficacy and Safety -- Use in Clinical Practice -- Other Pro-Hemostatic Therapies -- Clotting Factor Products -- Other -- The Search of a Universal Antidote -- Ciraparantag -- FXaI16L -- Conclusions -- References -- 6: Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrillation -- Introduction -- Risk Stratification: An Overview -- Embolic Risk Stratification -- CHADS2 -- CHA2DS2VASc -- R2CHADS2 Score -- Atria Stroke Score -- QStroke Score -- Garfield AF -- ABC Stroke Risk Score -- Bleeding Risk Assessment -- The HAS-BLED Score -- Direct Oral Anticoagulants in AF: General Outline -- DOACs and Risk Stratification -- DOACs Efficacy and Safety in Patients with AF and Diabetes -- DOACs and Heart Failure -- DOACs and Age ≥75 -- DOACs and Hypertension -- DOACs and Previous Stroke/TIA -- DOAC Efficacy and Safety in Female Patients with AF -- DOACs and Kidney Disease -- DOACs and Cirrhosis -- Anticoagulant Selection -- DOACs Registration Trials -- Oral Anticoagulant Selection -- New Scenarios in the Risk Stratification Panorama -- New Clinical Risk Factors -- BMI -- Echocardiography -- Biomarkers -- New Scores -- References -- 7: Use of DOAC in Patients with Kidney Disease -- Introduction -- Non-End-Stage Kidney Disease -- End-Stage Kidney Disease -- Patients on Dialysis -- Kidney Transplant Recipients -- Conclusions -- References -- 8: Anticoagulation in Elderly Patients with Atrial Fibrillation Authors -- Introduction -- Indications for Stroke Prevention in Elderly -- Antithrombotic Strategies in Elderly with AF: Anticoagulant Vs. Antiplatelet Therapy. DOACs in Elderly Patients: Current Evidences -- Dabigatran -- Rivaroxaban -- Apixaban -- Edoxaban -- VKA Versus DOACs in Elderly -- Anticoagulation in Frail Elderly -- Practical Choice of DOACs in Older Patients -- Conclusions -- References -- 9: The "Obesity Paradox" and the Use of NOAC -- Introduction -- Obesity Paradox in NVAF Patients -- Obesity Paradox in VTE Patients -- Body Weight and Use of NOACS: Pharmacological Considerations -- NOACs Versus Warfarin Across BMI Groups: Current Clinical Evidences -- NVAF Patients -- Dabigatran -- Rivaroxaban -- Apixaban -- Edoxaban -- NOACs Overview in NVAF Obese Patients -- VTE Obese Patients -- Dabigatran, Apixaban, and Edoxaban -- Rivaroxaban -- NOACs Overview in VTE Patients -- NVAF and VTE Obese Patients: Overview of NOACS Use -- Discussion -- Conclusion -- References -- 10: Direct Oral Anticoagulation in Cancer Patients -- Introduction -- Use of DOACs in AF Cancer Patients -- VTE in Cancer Patients: Are the DOACs Always the Best Choice? -- Primary Prevention of VTE in Cancer Patients -- Treatment of VTE in Cancer Patients -- Discussion -- Conclusion -- References -- 11: DOACs and Dementia in Patients with Atrial Fibrillation -- Introduction -- Atrial Fibrillation and Dementia -- Potential Mechanisms in the Association Between AF and Dementia -- Oral Anticoagulation and Dementia Risk -- DOACs and Dementia -- Future Directions -- Conclusions -- References -- 12: Non-vitamin K Antagonists and Cardiac Implantable Electronic Devices -- Introduction -- Pocket Hematomas -- Vitamin K Antagonists -- Non-vitamin K Oral Antagonists -- NOAC Interruption for CIED Surgery -- Concomitant Antiplatelet Therapy -- Predictors of Pocket Hematoma -- Anticoagulation of Patients with Subclinical Atrial Fibrillation -- Burden of SCAF -- Progression of SCAF -- Predictors of SCAF -- Anticoagulation for SCAF -- Ongoing Trials. References -- 13: Direct Oral Anticoagulants and Atrial Fibrillation Ablation -- Introduction -- Risk of Thromboembolism with AF Ablation -- Pre-ablation Anticoagulation Strategies -- Warfarin Management Periprocedurally -- DOAC Management Periprocedurally -- Intraprocedural Anticoagulation -- Postprocedural Anticoagulation -- Conclusions -- References -- 14: DOAC Therapy in Patients Post Left Atrial Appendage Occlusion or Isolation -- Stroke Reduction in Patients with Atrial Fibrillation -- Left Atrial Appendage Occlusion -- Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion -- Left Atrial Appendage Isolation -- Future Directions with Left Atrial Appendage Closure and Anticoagulation -- References -- 15: Use of Direct Oral Anticoagulants After Transcatheter Aortic Valve Replacement -- Introduction -- Technical Aspects of Transcatheter Bioprosthetic Heart Valves -- Thrombotic vs. Bleeding Risk -- Recent Percutaneous Coronary Intervention -- Atrial Fibrillation -- Cerebrovascular Complications -- Subclinical Leaflet Thrombosis -- Current Evidence and Future Perspectives -- References -- 16: Use of Direct Oral Anticoagulants After Percutaneous Coronary Intervention -- Introduction -- In the Middle of Ischemic and Bleeding Risk -- Lessons from Randomized Clinical Trials -- VKA in Triple Versus Dual Antithrombotic Therapy -- DOAC in Triple Versus Dual Antithrombotic Therapy -- PIONEER AF-PCI Trial -- RE-DUAL PCI Trial -- AUGUSTUS Trial -- ENTRUST-AF PCI Trial -- Meta-analysis -- Current Recommendations -- Practical Management of AF Patients Undergoing PCI -- Procedural and Peri-PCI Management -- Choice and Duration of Antithrombotic Therapy After PCI -- VKA in Triple Therapy in the DOAC Era: Is There Still Room? -- Other Interventional Strategies -- Conclusions -- References. 17: Direct Oral Anticoagulants and Left Ventricular Thrombosis: The Evidence for a Good Therapeutic Approach -- Introduction -- Epidemiology -- LVT in Dilated Cardiomyopathy -- High-Risk Patients -- Diagnostic Modalities -- Treatment Options -- Prevention of Embolic Events -- Treatment of Definite LVT -- Current International Guidelines -- Direct Oral Anticoagulants -- References -- Index. |
| Record Nr. | UNINA-9910488718103321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Psychological, Emotional, Social and Cognitive Aspects of Implantable Cardiac Devices / / edited by Riccardo Proietti, Gian Mauro Manzoni, Giada Pietrabissa, Gianluca Castelnuovo
| Psychological, Emotional, Social and Cognitive Aspects of Implantable Cardiac Devices / / edited by Riccardo Proietti, Gian Mauro Manzoni, Giada Pietrabissa, Gianluca Castelnuovo |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (XI, 296 p. 11 illus., 5 illus. in color.) |
| Disciplina | 616.12 |
| Soggetto topico |
Cardiology
Psychiatry |
| ISBN | 3-319-55721-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cognitive function in patients with congestive heart failure -- Heart brain connection in patients with ischemic heart disease -- Neurovegetative system and congestive heart failure -- Cognitive performance in the elderly -- Evolution and principle of pacing devices -- Hemodynamic performance of cardiac devices -- Impact of cardiac devices on QoL -- Pacemakers and cognitive performance -- Anxiety, depression and QoL in patients with ICD -- Emotional impact of device recall -- Cognitive impact of CRT. |
| Record Nr. | UNINA-9910254659903321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Stroke, Dementia and Atrial Fibrillation
| Stroke, Dementia and Atrial Fibrillation |
| Autore | Russo Vincenzo |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 electronic resource (212 p.) |
| Soggetto topico | Medicine |
| Soggetto non controllato |
memory loss
antioxidant neuroprotective acetylcholinesterase inhibitor molecular docking atrial fibrillation venous thrombosis anticoagulation perception chronic obstructive pulmonary disease atrial fibrillation cardiovascular risk outcome prognosis novel oral anticoagulants prosthetic valve replacement subclinical atrial fibrillation stroke ischemic cerebral events catheter ablation screening cognitive impairment atrial fibrillation ablation iatrogenic interatrial septum defect paradoxical embolism anticoagulant interruption cardioversion oral anticoagulation therapy left atrial appendage thrombosis transesophageal echocardiography IL1B IL1RN polymorphism inflammation cognitive decline rhythm control microbleeds cerebral ischemia diabetes mellitus metformin thiazolidinediones GLP-1 receptor agonists SGLT-2 inhibitors atrial high rate episodes NOACs non vitamin K oral anticoagulants oral anticoagulation intracerebral hemorrhage cerebral small vessel disease brain MRI circulating biomarkers direct oral anticoagulants (DOACs) atrial fibrillation (AF) electrical cardioversion (EC) surgical cryoablation left atrial function minimally invasive mitral valve repair echocardiography aneurysmal subarachnoid hemorrhage interdisciplinary setting metabolic syndrome obesity dementia |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557585603321 |
Russo Vincenzo
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||